H. Lundbeck A/S: Parkinson Disease trials

The registry lists 22 Parkinson Disease studies with H. Lundbeck A/S as lead sponsor. 2 are open to participants now and 7 have results posted.

Early Phase 1 1Phase 1 10Phase 2 5Phase 3 5Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor FluctuationsRecruitingNCT07514858Phase 2
• A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)RecruitingNCT07513441Phase 1
• An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease PatientsCompletedNCT02649608Phase 1Results posted
• A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa TherapyTerminatedNCT01927055Phase 3Results posted
• Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in ChinaCompletedNCT01556165Phase 3Results posted
• Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in ChinaCompletedNCT01479530Phase 3Results posted
• Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in KoreaCompletedNCT01268891Phase 3Results posted
• A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's DiseaseCompletedNCT01176240Phase 3Results posted
• Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's DiseaseCompletedNCT00125138Phase 2Results posted
• A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD)CompletedNCT06004180Phase 1
• Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy SubjectsTerminatedNCT04322227Phase 1
• Lu AF28996 in Participants With Parkinson's Disease (PD)CompletedNCT04291859Phase 1
• Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)TerminatedNCT04175132Phase 1
• A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy SubjectsCompletedNCT03826134Early Phase 1
• Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's DiseaseCompletedNCT03611569Phase 1
• Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)WithdrawnNCT03331848Phase 2
• Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's PatientsCompletedNCT03162874Phase 2
• A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female SubjectsCompletedNCT02639221Phase 1
• Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and WomenCompletedNCT01652313Phase 1
• Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's DiseaseWithdrawnNCT01331122Phase 1/2
• Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOnCompletedNCT01055379Phase 4
• Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy BodiesCompletedNCT00855686Phase 4